Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2010 | Letter to the Editor

Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Authors: Massimo Salvatori, Germano Perotti, Luca Giovanella, Massimo Eugenio Dottorini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2010

Excerpt

Dear Sir, …

Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:270–5. doi:10.1007/s00259-009-1261-3.

Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12:121–34.CrossRefPubMed

Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937–41.PubMedCrossRef

Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34:772–86.CrossRefPubMed

Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008;158:77–83.CrossRefPubMed

Park EK, Chung JK, Lim HH, Park DJ, Lee DS, Lee MC, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009;36:172–9.CrossRefPubMed

Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287–94.CrossRefPubMed

Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067–73.CrossRefPubMed

Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2009;47:952–4.CrossRefPubMed

10.

Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol (Oxf) 2007;67:547–51.

11.

Dietlein M, Moka D, Scheidhauer K, Schmidt M, Theissen P, Voth E, et al. Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests. Nucl Med Commun 2000;21:991–1000.CrossRefPubMed

12.

Chopra S, Wastie ML, Chan S, Vincent RM, Przeslak A, Perkins AC, et al. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 1996;17:687–91.CrossRefPubMed

13.

Verkooijen RBT, Verburg FA, van Isselt JW, Lips CJM, Smit JW, Stokkel MPM. The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies. Eur J Endocrinol 2008;159:301–7.CrossRefPubMed

Title: Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?
Authors: Massimo Salvatori
Germano Perotti
Luca Giovanella
Massimo Eugenio Dottorini
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1414-4

2024 ASCO Annual Meeting

Springer Medicine

Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2010

Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin)

Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer

Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours

High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications